CD8A and myeloid sarcoma: We think, that a more systematic analysis of CSF CD4/CD8 T cell ratio is needed in larger cohorts of neurosarcoidosis and MS patients, to sharpen the picture and to clearly determine the best cut-off value and the respective sensitivity, specificity, PLR and NLR for neurosarcoidosis vs. MS.